Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 12, 2018
Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group...
-
Dec 6, 2018Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
06 Dec 2018 KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018,...
-
Dec 5, 2018
CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...
-
Nov 26, 2018
This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative...
-
Nov 16, 2018
This news release is intended for Health Professional media only. 16 Nov 2018 Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that...
-
Nov 16, 2018
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. 16 Nov 2018 Seqirus, a...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Oct 29, 2018
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN...
-
Oct 22, 2018Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
22 Oct 2018 PHILADELPHIA, Pa. – October 22, 2018 – The University City Science Center and global biotechnology leader CSL Behring, which has its operational headquarters in King of Prussia,...
-
Oct 22, 2018ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
22 Oct 2018 LISBON, Portugal – 22 October 2018 – Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its “Current and Emerging...
-
Oct 19, 2018
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season. 19 Oct 2018 Seqirus, a global leader in...
Oct 11, 2018Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...
-
Oct 9, 2018CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
09 Oct 2018 Melbourne, 9 October, 2018 – CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts. The...
-
Sep 20, 2018
Barbara Angehrn joins Vifor Pharma as Chief Business Officer Patrick Treanor takes over from Scott Garland as President of Relypsa Vifor Pharma announced today changes to its management. Barbara...
-
Sep 18, 2018
Vifor Pharma Group increases equity stake in ChemoCentryx from 6.6% to 21.2%. Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (NASDAQ: CCXI) from...
-
Sep 18, 2018Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
18 Sep 2018 KING OF PRUSSIA, Pa. – September 18, 2018 – Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and...
-
Sep 13, 2018• Hosts Patient-Focused Symposium on Alpha 1 Management • Raises Money to Support Disease Awareness
13 Sep 2018 PARIS, France – 13 September 2018 – Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 17 September, during the 28th
-
Aug 28, 2018
Vifor Pharma today announced the launch of an inaugural Swiss Franc straight bond in the amount of CHF 465 million in the Swiss domestic market. The bond carries a 0.75% fixed coupon with a tenor...
-
Aug 23, 2018- The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size - IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
23 Aug 2018 KING OF PRUSSIA, Pa. – 23 August 2018 – Global biotherapeutics leader CSL Behring today announced that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein...
-
Aug 8, 2018
Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track #Strategic in-licensing deal concluded with Cara Therapeutics Inc Net sales and EBITDA guidance...
-
Jul 20, 2018• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin...
-
Jul 5, 2018- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment
- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients...
-
Jun 26, 2018
Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research New York, NY and Maidenhead, UK — 06/26/2018 The Human Vaccines Project, a nonprofit public-private...
-
Jun 22, 2018Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.
22 Jun 2018 KING OF PRUSSIA, Pa. – June 22, 2018 – An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring’s 2018 Prof. Heimburger Award...